Latest Breaking News On - டிராக் பதவி - Page 5 : comparemela.com

DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs

DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs Webcast of Earnings Call Today, May 4th at 4:30 p.m. ET News provided by Share this article Share this article CUPERTINO, Calif., May 4, 2021 /PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2021 and provided a corporate update. Q1 2021 Accomplishments: Initiated patient dosing in the Phase 2b AHFIRM clinical study of DUR-928 in severe Alcohol-associated Hepatitis (AH) FDA approval of POSIMIR in adults to produce post-surgical analgesia for up to 72 hours following Arthroscopic Subacromial Decompression Publication of DUR-928 s mechanism of action Appointment of two highly experienced biopharmaceutical board members

United statesJamese brownHuman servicesDrug administrationCompany epigenetic regulator programExchange commissionEpigenetic regulator programJournal of lipid researchUs department of healthCorporation nasdaqAgency for healthcare researchClinical developmentAlcohol associated hepatitisArthroscopic subacromial decompressionSelected programsTrack designation

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

Share: Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene s Proprietary Lymphodepletion Regimen ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May 19, 2021 at 2:30 p.m. PT/5:30 p.m. ET SOUTH SAN FRANCISCO, Calif. and PARIS, April 28, 2021 (GLOBE NEWSWIRE) Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent international pharmaceutical company, today announced that longer-term follow-up data from Allogene s dose escalation Phase 1 ALPHA study of ALL

United statesFrance generalFrederick lockeChristine cassianoRafael amadoSonia marquesAllogene therapeutics incAmerican society of clinical oncologyH lee moffitt cancer centerResearch developmentServier groupExchange commissionForum to reviewResearch instituteColorado blood cancer institute sarah cannonDepartment of blood

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in . Allogene Therapeutics, Inc.April 28, 2021 GMT Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene’s Proprietary Lymphodepletion Regimen ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May 19, 2021 at 2:30 p.m. PT/5:30 p.m. ET

United statesFrance generalFrederick lockeChristine cassianoRafael amadoSonia marquesAllogene therapeutics incAmerican society of clinical oncologyH lee moffitt cancer centerResearch developmentServier groupExchange commissionForum to reviewResearch instituteColorado blood cancer institute sarah cannonDepartment of blood

Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

Sanofi: New Dupixent (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years as young as 6 years Nearly 30 data presentations at AAD and ESPD across clinical and real-world settings, including the impact of Dupixent on disease measures in uncontrolled moderate-to-severe atopic dermatitis Late-breaking Phase 2 data for rilzabrutinib, an investigational therapy for pemphigus vulgaris, a rare, debilitating autoimmune disease, to be presented at AAD PARIS - April 23, 2021 - New analyses from Dupixent (dupilumab) trials evaluated infection incidence reduction and reinforced the need for no laboratory monitoring in patients six years and older with moderate-to-severe atopic dermatitis. Additional analyses evaluated response rates across a broad population, and the impact of Dupixent on disease extent and severity, quality of life (QoL), and itch. These and other data from real-world settings and clinical trials, in

United statesFrance generalEva schaefer jansenSebastien barbarotSuzanne grecoArnaud delepineJonathani silverbergFelix lauscherAmys pallerDedeef murrellStephan weidingerFara berkowitzMark boguniewiczSally bainNaimish patelAndrew blauvelt

Investegate |Sanofi Announcements | Sanofi: New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years

Investegate |Sanofi Announcements | Sanofi: New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United statesFrance generalEva schaefer jansenSebastien barbarotSuzanne grecoArnaud delepineJonathani silverbergFelix lauscherAmys pallerDedeef murrellStephan weidingerFara berkowitzMark boguniewiczSally bainNaimish patelAndrew blauvelt